FAST FACTS
FOUNDER(S):
David Smith
INNOVATION(S):
Medical Devices/Medical Diagnostics
EMPLOYEES:
40
HEADQUARTERS:
Los Angeles, CA
FOUNDED:
1999
REVENUE:
$7.1 million FY08
TSC MEMBER INSTITUTION(S):
University of Southern California
FUNDING AGENCY(S):
National Institutes of Health
STATUS:
Public
|
RESPONSE GENETICS, INC.
ABOUT THE COMPANY:
Response Genetics (RGI) is focused on the development and sale of molecular diagnostic tests for cancer. RGI’s technologies enable extraction and analysis of genetic information from tumor samples stored as formalin-fixed and paraffin-embedded specimens. Until this technique was invented at the University of Southern California, RNA was only available from fresh frozen specimens; it was not possible to extract meaningful genetic information from diagnostic specimens fixed and stored in paraffin.
In addition to diagnostic testing services, RGI generates revenue from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens for the pharmaceutical industry.
This exclusively licensed technology allows Response Genetics to deliver tangible results to pharmaceutical companies and to create new platforms to support the industry with more efficient, cost-effective analysis of clinical trial samples. That should lead to the development of more “personalized” patient therapies. Response Genetics has client relationships with some of the largest pharmaceutical companies in the world, including Roche, Roche Diagnostics, Taiho Pharmaceuticals and GlaxoSmithKline.
UNIVERSITY-BASED RESEARCH CONNECTION:
This technique was invented at the University of Southern California.
ROLE OF FEDERAL RESEARCH FUNDING:
The Response Genetics technologies were invented with the help of federal research funding from the National Cancer Institute, part of the National Institutes of Health.
 Read The Full Report Here
|
Printer-Friendly Version
RESPONSE GENETICS, INC.